Ticker League

Moderna (MRNA) Free Cash Flow Bridge

Pinpoint what moved Moderna's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

+60.78%

OCF YoY

+52.65%

Capex YoY

-86.05%

FCF Conversion Δ

Free cash flow bridge for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: $2.45B

FCF bridge breakdown for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$4.03B
  • Operating Cash Flow$1.61B
  • Capital Expenditure$845.00M
  • Free Cash Outflow−$1.58B
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation